Citation: E. Lee-lewandrowski et K. Lewandrowski, Regulatory compliance for point-of-care testing - A perspective from the United States (Circa 2000), CLIN LAB M, 21(2), 2001, pp. 241
Citation: E. Lee-lewandrowski et K. Lewandrowski, Selected topics in point-of-care testing - Urinalysis, pregnancy testing, microbiology, fecal occult blood, and other tests, CLIN LAB M, 21(2), 2001, pp. 389
Authors:
Keck, T
Balcom, JH
Antoniu, BA
Lewandrowski, K
Warshaw, AL
Fernandez-del Castillo, C
Citation: T. Keck et al., Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis, SURGERY, 130(2), 2001, pp. 175-181
Authors:
Lewandrowski, E
Mac Millan, D
Misiano, D
Tochka, L
Lewandrowski, K
Citation: E. Lewandrowski et al., Process improvement for bedside capillary glucose testing in a large academic medical center: the impact of new technology on point-of-care testing, CLIN CHIM A, 307(1-2), 2001, pp. 175-179
Authors:
Hicks, JM
Haeckel, R
Price, CP
Lewandrowski, K
Wu, AHB
Citation: Jm. Hicks et al., Recommendations and opinions for the use of point-of-care testing for hospitals and primary care: summary of a 1999 symposium, CLIN CHIM A, 303(1-2), 2001, pp. 1-17
Authors:
Januzzi, JL
Hahn, SS
Chae, CU
Giugliano, R
Lewandrowski, K
Theroux, P
Jang, IK
Citation: Jl. Januzzi et al., Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes, AM J CARD, 86(7), 2000, pp. 713-717